Pharsight

1. Fortical patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43580	UPSHER SMITH LABS	Nasal calcitonin formulations	Feb, 2021 (3 years ago)
USRE40812	UPSHER SMITH LABS	Nasal calcitonin formulation	Feb, 2021 (3 years ago)
US6440392	UPSHER SMITH LABS	Nasal calcitonin formulations	Feb, 2021 (3 years ago)

Market Authorisation Date: 12 August, 2005

Treatment: Nasal administration

Dosage: SPRAY, METERED;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 IU/spray	29 Mar, 2006	1		02 Feb, 2021	Extinguished

Strength	Dosage	Availability
200 IU/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SPRAY, METERED;NASAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101545	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US8889190	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US9555005	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US8652527	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US10363224	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	24 Dec, 2015	1		19 Mar, 2033	Extinguished Non-Forfeiture

Strength	Dosage	Availability
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
150MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (9 years from now)
US9662340	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (9 years from now)
US9622340	UPSHER SMITH LABS	Flexible circuit board and method for manufacturing same	Feb, 2034 (9 years from now)
US8785426	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 04, 2017

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

Strength	Dosage	Availability
12.5MG/1.25GM ACTUATION	GEL, METERED;TRANSDERMAL	Prescription
50MG/5GM PACKET	GEL;TRANSDERMAL	Prescription